Rinvoq Does Not Appear to Increase Risk of Rhabdomyolysis
Based on available evidence, Rinvoq (upadacitinib) is not associated with an increased risk of rhabdomyolysis. The FDA drug label and clinical trial data do not identify rhabdomyolysis as a recognized adverse event with this medication.
Evidence from FDA Drug Label
The official FDA prescribing information for Rinvoq lists multiple safety concerns including serious infections, malignancies, cardiovascular events, and venous thromboembolism, but rhabdomyolysis is not mentioned as a warning or adverse reaction 1.
Clinical Trial Safety Data
Extensive safety data from the SELECT clinical trial program encompassing over 15,000 patient-years of exposure across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and atopic dermatitis showed no signal for rhabdomyolysis 2. The comprehensive benefit-risk assessment across the phase III program in rheumatoid arthritis similarly did not identify rhabdomyolysis as a concern 3.
Creatine Phosphokinase (CPK) Elevations
While Rinvoq is associated with asymptomatic CPK elevations (rates of 4.4-7.9 per 100 patient-years), these are typically:
- Not accompanied by muscle weakness or pain
- Without clinical sequelae in the majority of patients
- Possibly related to restoration of muscle development rather than muscle damage 4
The EULAR consensus statement notes that one patient treated with a JAK inhibitor (class effect, not specifically upadacitinib) experienced rhabdomyolysis, but this appears to be an isolated case report rather than a pattern 4.
Clinical Monitoring Recommendations
If patients develop muscle symptoms while on Rinvoq:
- Check CPK levels only if symptomatic (muscle pain, weakness, or tenderness)
- Routine CPK monitoring is not necessary in asymptomatic patients 4
- Distinguish from other causes of myopathy (hypothyroidism, concomitant statin use, other medications)
Important Distinction from Statins
The evidence provided includes extensive discussion of statin-induced rhabdomyolysis 5, 6, 7, but these references are not relevant to Rinvoq. Statins have a well-established risk of rhabdomyolysis (approximately 1 in 23,000 patients), but this mechanism is entirely different from JAK inhibitor pharmacology.